Urofollitropin

Infertility Treatment

Urofollitropin is a hormone used to treat certain types of infertility in women. It provides follicle-stimulating hormone (FSH), which is necessary for the growth and development of eggs in the ovaries.

Ovulation Induction

This medication is used to induce ovulation in women who do not produce eggs naturally and who have not responded to other treatments. It helps the follicles in the ovary mature so that an egg can be released for fertilization.

Assisted Reproductive Technology (ART)

Urofollitropin is also used in medical procedures such as in vitro fertilization (IVF). In these cases, it is used to:

• Stimulate the ovaries to produce multiple eggs at once.
• Increase the number of eggs available for collection and fertilization.
• Support the development of healthy follicles during a controlled treatment cycle.

Urofollitropin is intended for use in women who have functional ovaries but are experiencing hormonal imbalances that prevent the natural development and release of eggs.

Mechanism of Action

Urofollitropin is a highly purified form of follicle-stimulating hormone (FSH). In the human body, FSH is naturally produced by the pituitary gland and is essential for the normal development and maturation of eggs in the ovaries.

When administered as a medication, urofollitropin works by directly stimulating the ovaries to produce follicles, which are the small, fluid-filled sacs that contain developing eggs. As these follicles grow, they produce estrogen, which helps prepare the lining of the uterus for a potential pregnancy.

Role in Fertility Treatment

Urofollitropin is used to help women achieve pregnancy through several processes:

• Follicle Development: It encourages the growth of one or more follicles in women who do not ovulate or who have irregular ovulation cycles.
• Multiple Egg Production: In assisted reproductive technologies, such as in vitro fertilization (IVF), it is used to stimulate the development of multiple follicles so that several eggs can be retrieved for fertilization.

Once the follicles have reached the appropriate size and maturity, another hormone called human chorionic gonadotropin (hCG) is typically administered. This second hormone triggers the final maturation of the egg and its release from the follicle (ovulation).

Common Side Effects

Many people using urofollitropin experience mild side effects. These may include:

• Headache
• Stomach pain, bloating, or gas
• Nausea or vomiting
• Pelvic pain or cramping
• Breast tenderness
• Redness, pain, or swelling at the injection site

Serious Side Effects

Seek medical attention immediately if you experience symptoms of Ovarian Hyperstimulation Syndrome (OHSS). This condition causes fluid to build up in the stomach and chest area and can be life-threatening. Symptoms include:

• Severe pain or swelling in the lower stomach area
• Rapid weight gain
• Severe nausea, vomiting, or diarrhea
• Decreased urination
• Shortness of breath

Other serious side effects that require prompt medical care include:

• Signs of a blood clot, such as sudden numbness, weakness, or pain and swelling in an arm or leg
• Severe allergic reactions, including rash, hives, itching, or trouble breathing
• Sudden, severe chest pain or a cough that produces blood
• Fever or chills

Urofollitropin also increases the risk of multiple births (such as twins or triplets) and ectopic pregnancy.

Ovarian Hyperstimulation Syndrome (OHSS)

Treatment with urofollitropin can lead to Ovarian Hyperstimulation Syndrome (OHSS), a condition where the ovaries become swollen and fluid leaks into the abdominal and chest areas. Severe OHSS is a medical emergency that can cause rapid weight gain, severe abdominal pain, nausea, vomiting, and decreased urination. If left untreated, it can lead to kidney failure or blood clots.

Multiple Births

This medication increases the chance of multiple pregnancies, such as twins or triplets. Multiple gestations are associated with an increased risk of maternal complications and premature birth.

Contraindications

Urofollitropin should not be used in individuals with certain medical conditions, including:

• Pregnancy or suspected pregnancy.
• Primary ovarian failure.
• Uncontrolled thyroid, pituitary, or adrenal gland disorders.
• Ovarian cysts or enlargement not caused by polycystic ovary syndrome (PCOS).
• Abnormal uterine bleeding of unknown cause.

Thromboembolic Risks

There is an increased risk of serious blood clots (thromboembolism) in the lungs, legs, or brain during or following treatment with gonadotropins. This risk is higher for individuals with a history of vascular disease or obesity.

Monitoring and Safety

Frequent clinical monitoring is required, including pelvic ultrasounds and blood tests to measure estradiol levels. These tests help healthcare providers monitor the ovarian response and adjust the dosage to prevent overstimulation. If the ovaries become excessively enlarged, the medication may be stopped to reduce the risk of OHSS or ovarian torsion (twisting of the ovary).

Other Risks

Individuals may have a higher risk of ectopic pregnancy (pregnancy outside the uterus) or miscarriage compared to natural conception. Additionally, there have been rare reports of ovarian tumors in individuals who have used fertility drugs for multiple treatment cycles.

Pregnancy

Urofollitropin is prescribed to help individuals become pregnant by stimulating egg production. It should not be used after pregnancy is achieved. If you suspect you are pregnant during treatment, notify your healthcare provider immediately. Clinical data suggests that when used as directed for fertility, it does not increase the risk of birth defects, but it is contraindicated for use during pregnancy.

Fertility treatments like urofollitropin increase the likelihood of multiple births, such as twins or triplets. Multiple pregnancies carry a higher risk of complications for both the parent and the fetuses.

Breastfeeding

It is currently unknown if urofollitropin is excreted in human breast milk. Because its effects on a nursing infant are not well understood, the use of this medication is generally not recommended while breastfeeding. Patients should consult with their doctor to weigh the potential risks and benefits before starting treatment while lactating.

Dosage Forms

Urofollitropin is supplied as a sterile, freeze-dried powder in single-use vials. It is intended for injection only after being reconstituted with a sterile diluent.

Administration Methods

• Subcutaneous injection: This method involves injecting the medication into the fatty tissue just beneath the skin.
• Intramuscular injection: This method involves injecting the medication directly into a muscle.

Available Strengths

This medication is most commonly available in vials containing 75 International Units (IU) of follicle-stimulating hormone (FSH) activity. It is typically packaged with a separate container of sterile diluent, such as sodium chloride solution, which is used to dissolve the powder before administration.

FDA Approval and Indications

Urofollitropin is a highly purified form of follicle-stimulating hormone (FSH) approved by the U.S. Food and Drug Administration (FDA) for specific fertility treatments. It is used to induce ovulation in women with polycystic ovary syndrome (PCOS) who have not responded to clomiphene citrate. It is also approved for controlled ovarian stimulation to help develop multiple follicles in women participating in Assisted Reproductive Technology (ART) programs, such as in vitro fertilization.

Safety and Monitoring

The FDA-approved labeling for urofollitropin includes warnings about several serious risks associated with its use. These include:

• Ovarian Hyperstimulation Syndrome (OHSS): A potentially life-threatening condition where the ovaries become severely swollen.
• Multiple Births: An increased risk of multiple gestations, such as twins or triplets.
• Vascular Complications: Risks related to blood clots and pulmonary issues.

There are no current Risk Evaluation and Mitigation Strategies (REMS) or boxed warnings associated with urofollitropin. Use of this medication requires close monitoring by a healthcare professional experienced in fertility treatments.

Factors Influencing Cost

Several factors determine the total out-of-pocket expense for urofollitropin treatment:

• Dosage and Duration: Because urofollitropin is used to stimulate follicle development, the amount needed depends on how an individual responds to the medication. Longer treatment cycles or higher doses will increase the total cost.
• Pharmacy Selection: Prices can differ between retail pharmacies and specialty pharmacies that focus on fertility medications.
• Administration Supplies: The cost of needles, syringes, and disposal containers may be separate from the medication itself.

Insurance Coverage

Insurance coverage for fertility treatments like urofollitropin is highly variable. Many health insurance plans do not cover infertility medications, or they may have a lifetime maximum benefit for fertility services. It is important to contact your insurance provider to determine if the drug is on their formulary and if prior authorization is required.

Financial Assistance

Because fertility treatments can be expensive, some patients may be eligible for financial assistance programs. These may include:

• Manufacturer-sponsored patient assistance programs for those who meet specific income requirements.
• Discount programs or coupons offered through specialty pharmacies.
• Fertility-specific financing or loan programs.